Product

TamiLife® Oral Suspension 6 mg/mL

Oseltamivir Phosphate – Antiviral Therapy for Influenza

TamiLife Oral Suspension contains Oseltamivir Phosphate, an antiviral medicine indicated for the treatment and prevention of Influenza A and B in adults, adolescents, children, and infants, including full-term newborns.
It is specially formulated for patients who have difficulty swallowing capsules, ensuring accurate dosing across all age groups.

Key Ingredients and Benefits

Oseltamivir Phosphate (6 mg/mL)

Pharmacological Class: Antiviral – Neuraminidase Inhibitor

Key Benefits:

• Inhibits Influenza Virus Replication:
  Oseltamivir selectively blocks neuraminidase enzymes on the surface of Influenza A and B viruses, preventing the release and spread of viral particles from infected cells.

• Reduces Duration of Influenza Symptoms:
  When administered within 48 hours of symptom onset, it helps shorten the duration of fever, cough, sore throat, headache, and muscle pain.

• Decreases Severity of Illness:
  Lowers viral load in the respiratory tract, leading to milder clinical symptoms and faster recovery.

• Prevents Influenza-Related Complications:
  Reduces the risk of complications such as pneumonia, bronchitis, and otitis media, particularly in children and high-risk patients.

• Suitable for Pediatric Use:
  Oral suspension formulation allows accurate, weight-based dosing for infants, children, and patients who cannot swallow capsules.

• Well-Tolerated Antiviral Therapy:
  Demonstrates a favorable safety profile when used as prescribed under medical supervision.

How Tamilife Works?

TamiLife Oral Suspension contains Oseltamivir Phosphate, an antiviral agent that interferes with the influenza virus life cycle and limits its spread within the body.

1. Blocks Viral Release

Oseltamivir selectively inhibits neuraminidase enzymes found on the surface of Influenza A and B viruses. These enzymes are required for newly formed viral particles to be released from infected respiratory cells. By blocking this process, TamiLife prevents the virus from spreading to healthy cells.

2. Reduces Viral Replication

By limiting the release of viral particles, TamiLife reduces overall viral replication in the respiratory tract. This helps control infection progression, especially when treatment is started within 48 hours of symptom onset.

3. Shortens Illness Duration

Lower viral load leads to reduced inflammation and milder symptoms such as fever, cough, sore throat, and muscle pain, helping patients recover faster.

4. Lowers Risk of Complications

Early control of viral spread reduces the likelihood of influenza-related complications, including pneumonia, bronchitis, and secondary infections, particularly in children, elderly patients, and other high-risk groups.

Why Choose TamiLife Oral Suspension?

• Suitable for infants, children, and patients with swallowing difficulties

• Clinically proven antiviral therapy

• Enables accurate weight-based dosing

• Reduces influenza severity and complications

• Manufactured according to high pharmaceutical quality standards